In formulations or medicinal preparation the Active Pharmaceutical Ingredient are the substances, which are responsible for therapeutic activity. The quality of a medicinal preparation is related to all the factors, which contribute directly or indirectly to the safety, stability effectiveness & acceptability of the products. These molecules are obtained from various sources like naturally occurring substances, semi synthetic and synthetic routes. Therefore the quality must be built in the products during the research and development stage of the product itself. A large number of appropriate reagents solvents and synthetic routes are used to bring about the reaction of a pharmaceutically active molecule. As a result during the preparation of the molecule many unwanted but related compounds and byproducts may form along with the required molecule. Appropriate methods are developed to purify the reaction product to obtain the Active Pharmaceutical Ingredient to maximum purity. These impurities are also termed as related substance in the Pharmacopoeia or official texts. These impurities when they are present within the limits prescribed in the pharmacopoeia are harmless. Thus it is necessary to have these impurities in a pure form, so that we can compare the purity of the drug. In the present study related substance of cephalexin an antibiotic drug were synthesized, and the impurities are then compared identified and quantified using analytical methods such as HPLC.
Introduction
Impurity is defined as any substance coexisting with the original drug, such as starting material or intermediates or that is formed, due to any side reactions. Impurity can be of three types: Impurities closely related to the product and coming from the chemical or from the biosynthetic route itself, Impurities formed due to spontaneous decomposition of the drug during the storage or on exposure to extreme conditions, or the precursors which may be present in the final product as impurities. Impurities present in excess of 0.1% should be identified and quantified by selective methods. The suggested structures of the impurities can be synthesized and will provide the final evidence for their structures, previously determined by spectroscopic methods. Therefore it is essential to know the structure of these impurities in the bulk drug in order to alter the reaction condition and to reduce the quantity of impurity to an acceptable level.
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Isolation, identification and quantification of impurities help us in various ways, to obtain a pure substance with less toxicity and, safety in drug therapy. Quantitative determination of these impurities could be used as a method for the quality control and validation of drug substances. Regulatory authorities such as US FDA, WHO, TGA, and MCA insist on the impurity profiling of drugs. 18, 20, 27 Classification of Impurities 2) 7-Aminodesacetoxy Cephalosporonic Acid (7-ADCA) Objectives For the identification of the related substances in the Active Pharmaceutical Ingredient it is necessary to have knowledge of their chemical structure. Based on the structure, pure samples of the impurities themselves have to be synthesized and their structure determined by spectroscopic and chromatographic techniques. These pure samples of the impurities are then compared with the related substances, which may be present in the synthesized Active Pharmaceutical Ingredient. Once the related substances are identified the concentration levels of the related substances in the Active Pharmaceutical Ingredient can be determined by chromatographic techniques. The related substances and their concentrations are determined by comparison with the synthesized pure related substances and thereby a proof is obtained that their limits are well within those prescribed in the pharmacopoeia. Then the Active Pharmaceutical Ingredient is deemed as acceptable for formulation. Therefore it was observed that this kind of works finds much importance in maintaining the purity of an Active Pharmaceutical Ingredient and in identification of the related substances in the synthesized Active Pharmaceutical Ingredient. Hence the related substances can be identified if they were present in the manufactured Active Pharmaceutical Ingredient within the prescribed limits. Calculate the known impurities using formula;
At/As X ws / 50 X 2/25 X 5/wt X P/100 X 100 Where, At=Area of Impurity peak. 
Conclusion
The study of impurity profiles of a bulk drug is the thrust area of research in bulk drug industry. It is useful in identifying the impurities of drug and thus providing scope for a better product with high purity and quality. Hence an attempt was made to identify the impurities in Cephalexine, two possible impurities of Cephalexin were characterized by HPLC. From, result it was concluded that the given sample of cephalexin (API) was passes the related substance test, as all the impurities (known and unknown) within the limit a per USP specification. 
